RU2409364C2 - 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ - Google Patents

3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ Download PDF

Info

Publication number
RU2409364C2
RU2409364C2 RU2008108516/15A RU2008108516A RU2409364C2 RU 2409364 C2 RU2409364 C2 RU 2409364C2 RU 2008108516/15 A RU2008108516/15 A RU 2008108516/15A RU 2008108516 A RU2008108516 A RU 2008108516A RU 2409364 C2 RU2409364 C2 RU 2409364C2
Authority
RU
Russia
Prior art keywords
dihydrotetrabenazine
isomer
cis
cells
isomers
Prior art date
Application number
RU2008108516/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2008108516A (ru
Inventor
Эндрю Джон ДАФФИЛД (GB)
Эндрю Джон ДАФФИЛД
Original Assignee
Байовейл Лэборетериз Интернешнл (Барбадос) Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байовейл Лэборетериз Интернешнл (Барбадос) Срл filed Critical Байовейл Лэборетериз Интернешнл (Барбадос) Срл
Publication of RU2008108516A publication Critical patent/RU2008108516A/ru
Application granted granted Critical
Publication of RU2409364C2 publication Critical patent/RU2409364C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
RU2008108516/15A 2005-08-05 2006-08-04 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ RU2409364C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0516168.2 2005-08-05
GBGB0516168.2A GB0516168D0 (en) 2005-08-05 2005-08-05 Pharmaceutical compounds

Publications (2)

Publication Number Publication Date
RU2008108516A RU2008108516A (ru) 2009-09-10
RU2409364C2 true RU2409364C2 (ru) 2011-01-20

Family

ID=34984180

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2008108516/15A RU2409364C2 (ru) 2005-08-05 2006-08-04 3,11b-ЦИС-ДИГИДРОТЕТРАБЕНАЗИН ДЛЯ ЛЕЧЕНИЯ ПРОЛИФЕРАТИВНОГО ЗАБОЛЕВАНИЯ ИЛИ ВОСПАЛЕНИЯ

Country Status (23)

Country Link
US (1) US20090275605A1 (enExample)
EP (2) EP1964565A1 (enExample)
JP (1) JP2009503045A (enExample)
KR (1) KR20080033501A (enExample)
CN (1) CN101321528B (enExample)
AT (1) ATE412414T1 (enExample)
AU (1) AU2006277836B8 (enExample)
CA (1) CA2620952A1 (enExample)
CY (1) CY1108729T1 (enExample)
DE (1) DE602006003415D1 (enExample)
DK (1) DK1861100T3 (enExample)
ES (1) ES2317564T3 (enExample)
GB (1) GB0516168D0 (enExample)
HR (1) HRP20090017T3 (enExample)
MX (1) MX2008001546A (enExample)
NZ (1) NZ566010A (enExample)
PL (1) PL1861100T3 (enExample)
PT (1) PT1861100E (enExample)
RS (1) RS50720B (enExample)
RU (1) RU2409364C2 (enExample)
SI (1) SI1861100T1 (enExample)
WO (1) WO2007017643A1 (enExample)
ZA (2) ZA200801170B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
DK2081929T3 (da) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Substituerede 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11B-hexahydro-2H-pyrido[2,1-A]isoquinolin-2-ol-forbindelser og fremgangsmåder angående disse
GB0721669D0 (en) * 2007-11-02 2007-12-12 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463451A (en) 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
US20120003330A1 (en) 2010-06-01 2012-01-05 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
CN102285984B (zh) * 2010-11-25 2012-10-10 江苏威凯尔医药科技有限公司 (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
KR20160111999A (ko) 2014-01-27 2016-09-27 오스펙스 파마슈티칼스, 인코포레이티드 소포성 모노아민 수송체 2의 벤조퀴놀린 억제제
MA41177A (fr) * 2014-12-15 2017-10-24 Esteve Labor Dr Utilisation de ligands des récepteurs sigma dans l'arthrose
US10550120B2 (en) 2016-03-25 2020-02-04 Tohoku University Indole alkaloid compound having immune checkpoint inhibitory action
CN109283279B (zh) * 2017-07-21 2019-11-01 南京正大天晴制药有限公司 通过高效液相色谱法分离测定雷替曲塞及其对映异构体的方法
CN109283263B (zh) * 2017-07-21 2019-06-25 南京正大天晴制药有限公司 用于雷替曲塞合成质量控制的检测分析方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830993A (en) * 1958-04-15 Quinolizine derivatives

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3009918A (en) * 1961-11-21 Chz ch
US3132147A (en) * 1964-05-05
US3209005A (en) * 1965-09-28 Hexahydro-llbh-benzo[a] quinolizines and processes therefor
US3079395A (en) * 1963-02-26 Novel z-oxq-benzoquinoliaine
US3095419A (en) * 1963-06-25 Process for preparing z-oxo-j-
US3123609A (en) * 1964-03-03 Benzo
US3159638A (en) * 1964-12-01 Xcha-chj
US3314966A (en) * 1967-04-18 Substituted benzo[a]quinolizines
US2954382A (en) * 1960-09-27 Xpreparation of hexahydrobenzoquinol-
US2843591A (en) 1958-07-15 Method for preparing same
US3053845A (en) * 1962-09-11 Benzofykedocolines
US3045021A (en) * 1959-09-24 1962-07-17 Hoffmann La Roche Preparation of substituted 2-oxobenzoquinolizines
GB999092A (en) * 1959-11-24 1965-07-21 Wellcome Found Method for making benzo(a)-quinolizine derivatives
US3375254A (en) * 1961-09-29 1968-03-26 Burroughs Wellcome Co Manufacture of 1, 2, 3, 4, 6, 7-hexahydro-2-oxo-11bh-benzo(a)quinolizines
US3105079A (en) * 1961-12-29 1963-09-24 Pfizer & Co C 10-aminobenzopyridocolines
US3390152A (en) * 1965-10-21 1968-06-25 Abbott Lab 9, 10-alkoxy-3-alkyl-2, 2-(dithiosubstituted)-benzoquinolizines
US3634431A (en) * 1969-12-22 1972-01-11 Miles Lab Acylated and alkylated derivatives of 2-aminohexahydrobenzo(a)quinolizines
US3635986A (en) * 1969-12-22 1972-01-18 Miles Lab 2-substituted amino-hexahydrobenzo(a)quinolizines
YU264675A (en) * 1974-10-23 1982-05-31 Chinoin Gyogyszer Es Vegyeszet Process for obtaining benzo (a)-quinolizidine derivatives
GB1513824A (en) * 1975-05-22 1978-06-14 Wyeth John & Brother Ltd 1,3,4,6,7,11b-hexahydro-2h-benzo(a)quinolizine derivative
US4133812A (en) * 1975-11-21 1979-01-09 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt. Process for producing benzo (a) quinolizine derivatives
US4304913A (en) * 1978-11-20 1981-12-08 Miles Laboratories, Inc. Trans-2-substituted-amido-hexahydrobenzo [A]quinolizines
US4353656A (en) * 1980-10-14 1982-10-12 Xerox Corporation Moving coil, multiple energy print hammer system including a closed loop servo
US4778054A (en) * 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AU591152B2 (en) * 1985-07-30 1989-11-30 Glaxo Group Limited Devices for administering medicaments to patients
GB9004781D0 (en) * 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2794742B1 (fr) * 1999-06-11 2005-06-03 Sanofi Synthelabo Nouveaux derives du benzene, un procede pour leur preparation et les compositions pharmaceutiques les contenant
US6632666B2 (en) * 2000-01-14 2003-10-14 Biolife Solutions, Inc. Normothermic, hypothermic and cryopreservation maintenance and storage of cells, tissues and organs in gel-based media
BR0110302A (pt) * 2000-04-18 2003-01-14 Agouron Pharma Compostos de pirazol para inibição de proteìnas cinase, sal e pró-droga farmaceuticamente aceitável, metabólito farmaceuticamente ativo ou sal farmaceuticamente aceitável de metabólito, composição farmacêutica, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase, método de modulação ou inibição da atividade de um receptor de proteìna cinase
PL1638529T3 (pl) * 2003-06-16 2017-03-31 Andrx Pharmaceuticals, Llc. Kompozycja doustna o przedłużonym uwalnianiu
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds
KR100682506B1 (ko) * 2005-01-18 2007-02-15 (주)젠크로스 프라지콴텔, 또는 이의 염을 포함하는 약학 조성물
GB0514501D0 (en) * 2005-07-14 2005-08-24 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2462611A (en) * 2008-08-12 2010-02-17 Cambridge Lab Pharmaceutical composition comprising tetrabenazine
US20110053866A1 (en) * 2008-08-12 2011-03-03 Biovail Laboratories International (Barbados) S.R.L. Pharmaceutical compositions
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463452A (en) * 2008-09-08 2010-03-17 Cambridge Lab Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830993A (en) * 1958-04-15 Quinolizine derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Kilbourn М et al. Binding of alpha-dihydrotetrabenazine to the vesicular monoamine transporter is stereospecific. Eur J Pharmacol. 1995 May 24; 278(3):249-52. Mehvar R. et al. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studiesDrug Metab Dispos. 1987 Mar-Apr; 15(2):250-5. (реферат) [он-лайн] [найдено 2010-02-27] Найдено из базы данных PubMed PMID:2882986. *
ХАРКЕВИЧ Д.А. Фармакология. - М.: Медицина, 1996 с.163-170. *

Also Published As

Publication number Publication date
CY1108729T1 (el) 2014-04-09
DE602006003415D1 (de) 2008-12-11
DK1861100T3 (da) 2008-12-15
AU2006277836A1 (en) 2007-02-15
ZA200801171B (en) 2009-08-26
HK1111084A1 (en) 2008-08-01
ES2317564T3 (es) 2009-04-16
CN101321528B (zh) 2011-05-25
NZ566010A (en) 2010-05-28
GB0516168D0 (en) 2005-09-14
PL1861100T3 (pl) 2009-06-30
SI1861100T1 (sl) 2009-04-30
HRP20090017T3 (hr) 2009-03-31
EP1861100B1 (en) 2008-10-29
RS50720B (sr) 2010-08-31
ZA200801170B (en) 2009-12-30
RU2008108516A (ru) 2009-09-10
MX2008001546A (es) 2008-04-04
AU2006277836B2 (en) 2011-11-10
ATE412414T1 (de) 2008-11-15
WO2007017643A1 (en) 2007-02-15
CA2620952A1 (en) 2007-02-15
CN101321528A (zh) 2008-12-10
PT1861100E (pt) 2008-12-26
EP1964565A1 (en) 2008-09-03
KR20080033501A (ko) 2008-04-16
AU2006277836B8 (en) 2011-12-08
EP1861100A1 (en) 2007-12-05
JP2009503045A (ja) 2009-01-29
US20090275605A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
CA2942883C (en) 1,3-benzodioxole derivative
JP6920295B2 (ja) テトラヒドロナフタレンエストロゲン受容体モジュレーター及びその使用
CN113164495B (zh) E3连接酶的共价靶向
AU2006277836B8 (en) 3 , llb-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
US11952349B2 (en) Anti-cancer nuclear hormone receptor-targeting compounds
EP3999507B1 (en) Imidazo[4,5-c]pyridine derivatives as toll-like receptor agonsits
SG11202111402PA (en) Anti-cancer nuclear hormone receptor-targeting compounds
JP2021515010A (ja) フェロトーシス誘導活性を有する化合物およびそれらの使用方法
WO2014023081A1 (zh) 青嵩素衍生物及其制法和应用
KR20230160299A (ko) 항암 핵 호르몬 수용체 표적화 화합물
TW202012384A (zh) 特定芳基普拉二烯內酯化合物及其使用方法
WO2016022955A1 (en) Compounds and methods for treating cancer
WO2014170704A1 (en) Deuterated morphine derivatives
KR20210027382A (ko) 접히지 않은 단백질 반응의 활성화제
US20240139149A1 (en) Therapeutic uses of urolithin derivatives
WO2008052352A1 (en) Substituted quinone indoleamine 2,3-dioxygenase (ido) inhibitors and syntheses and uses therefor
JP2025508983A (ja) 重水素化レチノイド化合物ならびにその合成および使用
WO2022020605A1 (en) Treatment of metastasized estrogen receptor positive breast cancer
HK1121405A (en) 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
HK1111084B (en) 3,11b-cis-dihydrotetrabenazine for the treatment of a proliferative disease or an inflammation
HK40119554A (en) Small molecule inhibitors of lanosterol synthase
JP2025510303A (ja) ラノステロール合成酵素の低分子阻害剤
EA048477B1 (ru) Противоопухолевые соединения, направляющие на ядерный рецептор гормона

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20120805